Question 1

What is PEN's 52-week high and low?

Accepted Answer

In the last 52 weeks, Penumbra reached a high of $310.00 (on February 19, 2025) and a low of $148.00 (on July 31, 2024).

Question 2

What is the market cap and P/E ratio for PEN?

Accepted Answer

Curious about Penumbra's size and valuation? Its market capitalization stands at 9.85B. When it comes to valuation, the P/E ratio (trailing twelve months) is 235.61, and the forward P/E (looking ahead) is 67.32.

Question 3

Does PEN pay dividends? If so, what's the yield?

Accepted Answer

As for dividends, Penumbra isn't currently offering a significant yield, or that specific data isn't available right now.

Question 4

Who are Penumbra's main competitors or similar companies to consider before investing?

Accepted Answer

When looking at Penumbra, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Abbott Laboratories ABT	231.85B	Healthcare	Medical Devices	29.24%	23.05%
Boston Scientific BSX	149.87B	Healthcare	Medical Devices	36.54%	175.69%
Stryker SYK	147.95B	Healthcare	Medical Devices	17.21%	96.77%
Medtronic plc MDT	110.29B	Healthcare	Medical Devices	13.89%	-1.22%
Edwards Lifesciences EW	43.31B	Healthcare	Medical Devices	-16.82%	-21.95%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

Question 5

What are the key financial health indicators for Penumbra Inc.? (e.g., ROE, Debt/Equity)

Accepted Answer

To get a sense of Penumbra's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 3.50%, the Debt to Equity ratio from the most recent quarter is 18.19, and its Gross Profit Margin stands at 66.60%.

Question 6

What is the recent revenue and earnings growth for PEN?

Accepted Answer

Looking at Penumbra's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 16.30%, and quarterly earnings saw a YoY growth of 256.50%.

Question 7

How much of PEN stock is held by insiders and institutions?

Accepted Answer

Wondering who owns Penumbra stock? Company insiders (like executives and directors) hold about 3.57% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 91.85%.

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Penumbra PEN	9.85B Mid-cap	-3.22%	-3.17%	-5.74%	-1.53%	3.49%	38.64%	86.11%	30.85%
Abbott Laboratories ABT	231.85B Mega-cap	-1.70%	0.22%	7.08%	17.90%	17.86%	29.24%	23.05%	44.50%
Boston Scientific BSX	149.87B Large-cap	-3.33%	3.79%	13.43%	12.87%	16.17%	36.54%	175.69%	200.81%
Stryker SYK	147.95B Large-cap	-0.79%	2.68%	13.66%	10.51%	9.42%	17.21%	96.77%	122.20%
Medtronic plc MDT	110.29B Large-cap	0.57%	0.25%	5.44%	9.77%	9.29%	13.89%	-1.22%	-2.66%
Edwards Lifesciences EW	43.31B Large-cap	-1.94%	0.43%	11.14%	4.14%	5.65%	-16.82%	-21.95%	13.23%

Penumbra (PEN) | Stock Overview & Key Data

Penumbra Performance Comparison

Stock Range

Today's Range

52 Week Range

Key Statistics

Financial Highlights

Profitability

Returns and Earnings

Growth

Peer Performance Comparison

Ownership & Short Interest

Penumbra Recurring Investment / Dollar-Cost Averaging Calculator

Frequently Asked Questions